Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for the Week Ending March 28, 2020

3/31/2020

 
Regulatory Update
 
The FDA approved ozanimod (Zeposia, Bristol Myers Squibb) on 3/25/2020 for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BMS announced it would delay the launch for an unspecified time due to the COVID-19 pandemic. Pricing will be announced shortly before launch.
 
The FDA accepted the NDA for bupivacaine hydrochloride collagen-matrix for the management of postsurgical pain after open inguinal hernia surgery and set a PDUFA date of 8/26/2020.
 
The FDA requested additional information on beta beglogene darolentivec manufacturing; therefore Bluebird has delayed submission of a BLA to mid-2021.
 
Announced Research Updates
 
VBL Therapeutics announced positive interim results from 60 patients enrolled in the 400 patient, Phase III OVAL trial, where treatment with ofranergene obadenovec plus paclitaxel demonstrated a 58% overall response rate in patients with platinum-resistant ovarian cancer.
 
Inovio announced 6-month interim results from 20 patients enrolled in an 88-week, Phase II trial, where treatment with VGX-3100 resulted in an overall decrease in the number of lesions in 15/20 patients with 10/20 demonstrating clearance of HPV-16/18 associated precancerous lesions in adults with precancerous anal dysplasia caused by HPV-16 and/or HPV-18.
 
MyoKardia announced that in the 16-week, 59 patient, Phase II MAVERICK-HCM trial, treatment with mavacamten resulted in a 53% reduction in serum NT-proBNP compared to 1% reduction with placebo in patients with symptomatic, non-obstructive hypertrophic cardiomyopathy.
 
Published Research Updates
 
In the Phase III, ARCTIC trial, tremelimumab added to durvalumab improved overall survival and progression-free survival in heavily pretreated patients with metastatic non-small cell lung cancer. 
 
In a 15-week, 57 patient, Phase II trial, treatment with tavapadon reduced the MDS-UPDRS Part III score by 9.0 points compared to a 4.3 point decrease with placebo in patients with early-stage Parkinson's disease.
 
In a 70 patient trial, levosimendan was comparable to milrinone on myocardial function after pediatric cardiac surgery.
 
In the 146 patient, Phase IIb, open-label, FIGHT-202 trial, treatment with pemigatinib resulted in an overall response in 38/107 patients with cholangiocarcinoma with FGFR2 fusions or rearrangements.
 
In the 371 patient, Phase III BRIGHTE trial, fostemsavir was added to a failing antiviral regimen in patients with resistant infections or intolerance to a regimen. After 8 days the HIV-1 RNA level was 0.79 log10 copies per milliliter in the fostemsavir group and 0.17 log10 copies in the placebo group. At 48 weeks 54% of randomized patients and 38% of non-randomized patients maintained virologic suppression (<40 c/mL).
 
In a 5,050 patient, Phase III VICTORIA trial, 35.5% of patients treated with vericiguat experienced the primary outcome (composite of death from cardiovascular causes or first hospitalization for heart failure) compared to 38.5% in the placebo group in patients with chronic heart failure and an ejection fraction of less than 45% that were receiving guideline-based medical therapy.
 
In the Phase III, BETonMACE trial, apabetalone added to standard of care did not reduce major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or stroke) compared to placebo in high-risk patients with type 2 diabetes, recent acute coronary syndrome, and low HDL cholesterol.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.